Brokerages Set Axon Enterprise, Inc (NASDAQ:AXON) Price Target at $815.00

Axon Enterprise, Inc (NASDAQ:AXON) has earned a consensus rating of “Moderate Buy” from the eighteen analysts that are presently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $802.7143.

AXON has been the topic of a number of recent research reports. JMP Securities reaffirmed a “market outperform” rating and issued a $825.00 target price on shares of Axon Enterprise in a report on Monday, September 29th. Piper Sandler reduced their target price on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Barclays decreased their target price on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. UBS Group dropped their price target on Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Finally, Royal Bank Of Canada started coverage on Axon Enterprise in a research report on Monday, November 17th. They set an “outperform” rating and a $860.00 price objective for the company.

Insider Activity

In other news, President Joshua Isner sold 20,000 shares of the firm’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $552.60, for a total value of $11,052,000.00. Following the completion of the sale, the president owned 249,502 shares in the company, valued at approximately $137,874,805.20. This trade represents a 7.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Jennifer H. Mak sold 894 shares of Axon Enterprise stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $550.00, for a total transaction of $491,700.00. Following the completion of the sale, the chief accounting officer directly owned 13,514 shares in the company, valued at approximately $7,432,700. The trade was a 6.20% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 64,406 shares of company stock valued at $38,521,038. 5.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Axon Enterprise

A number of hedge funds have recently added to or reduced their stakes in AXON. Allworth Financial LP increased its position in Axon Enterprise by 1.0% during the 3rd quarter. Allworth Financial LP now owns 5,792 shares of the biotechnology company’s stock worth $4,156,000 after purchasing an additional 58 shares during the period. Swiss Life Asset Management Ltd grew its holdings in Axon Enterprise by 23.5% during the third quarter. Swiss Life Asset Management Ltd now owns 14,153 shares of the biotechnology company’s stock worth $10,157,000 after acquiring an additional 2,694 shares during the period. Strategic Advocates LLC raised its position in Axon Enterprise by 1.2% in the third quarter. Strategic Advocates LLC now owns 1,856 shares of the biotechnology company’s stock worth $1,332,000 after acquiring an additional 22 shares in the last quarter. CIBC Private Wealth Group LLC lifted its holdings in Axon Enterprise by 26.4% in the third quarter. CIBC Private Wealth Group LLC now owns 186,538 shares of the biotechnology company’s stock valued at $133,867,000 after acquiring an additional 38,966 shares during the period. Finally, CIBC Bancorp USA Inc. acquired a new stake in Axon Enterprise in the third quarter valued at $9,718,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Up 1.0%

Axon Enterprise stock opened at $600.19 on Tuesday. The company has a market capitalization of $47.36 billion, a P/E ratio of 189.93, a PEG ratio of 136.47 and a beta of 1.40. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12. Axon Enterprise has a fifty-two week low of $469.24 and a fifty-two week high of $885.91. The stock has a 50-day simple moving average of $606.02 and a 200-day simple moving average of $705.83.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The firm had revenue of $710.64 million for the quarter, compared to analysts’ expectations of $704.83 million. During the same quarter in the prior year, the business earned $1.45 EPS. The company’s quarterly revenue was up 30.6% compared to the same quarter last year. Equities research analysts expect that Axon Enterprise will post 5.8 earnings per share for the current year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.